MAPK3 and neoplasm: In metastatic colon cancer, deregulation of the RAS-MEK1/2-ERK1/2 signaling pathway downstream of epidermal growth factor receptor by RAS-associated mutations confers a selective growth and survival advantage to tumor cells giving them an acquired resistance to anti-EGFR therapy [18].